Cargando…

Experience of targeted Usher exome sequencing as a clinical test

We show that massively parallel targeted sequencing of 19 genes provides a new and reliable strategy for molecular diagnosis of Usher syndrome (USH) and nonsyndromic deafness, particularly appropriate for these disorders characterized by a high clinical and genetic heterogeneity and a complex struct...

Descripción completa

Detalles Bibliográficos
Autores principales: Besnard, Thomas, García-García, Gema, Baux, David, Vaché, Christel, Faugère, Valérie, Larrieu, Lise, Léonard, Susana, Millan, Jose M, Malcolm, Sue, Claustres, Mireille, Roux, Anne-Françoise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907913/
https://www.ncbi.nlm.nih.gov/pubmed/24498627
http://dx.doi.org/10.1002/mgg3.25
_version_ 1782301681074044928
author Besnard, Thomas
García-García, Gema
Baux, David
Vaché, Christel
Faugère, Valérie
Larrieu, Lise
Léonard, Susana
Millan, Jose M
Malcolm, Sue
Claustres, Mireille
Roux, Anne-Françoise
author_facet Besnard, Thomas
García-García, Gema
Baux, David
Vaché, Christel
Faugère, Valérie
Larrieu, Lise
Léonard, Susana
Millan, Jose M
Malcolm, Sue
Claustres, Mireille
Roux, Anne-Françoise
author_sort Besnard, Thomas
collection PubMed
description We show that massively parallel targeted sequencing of 19 genes provides a new and reliable strategy for molecular diagnosis of Usher syndrome (USH) and nonsyndromic deafness, particularly appropriate for these disorders characterized by a high clinical and genetic heterogeneity and a complex structure of several of the genes involved. A series of 71 patients including Usher patients previously screened by Sanger sequencing plus newly referred patients was studied. Ninety-eight percent of the variants previously identified by Sanger sequencing were found by next-generation sequencing (NGS). NGS proved to be efficient as it offers analysis of all relevant genes which is laborious to reach with Sanger sequencing. Among the 13 newly referred Usher patients, both mutations in the same gene were identified in 77% of cases (10 patients) and one candidate pathogenic variant in two additional patients. This work can be considered as pilot for implementing NGS for genetically heterogeneous diseases in clinical service.
format Online
Article
Text
id pubmed-3907913
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Wiley Periodicals
record_format MEDLINE/PubMed
spelling pubmed-39079132014-02-04 Experience of targeted Usher exome sequencing as a clinical test Besnard, Thomas García-García, Gema Baux, David Vaché, Christel Faugère, Valérie Larrieu, Lise Léonard, Susana Millan, Jose M Malcolm, Sue Claustres, Mireille Roux, Anne-Françoise Mol Genet Genomic Med Original Articles We show that massively parallel targeted sequencing of 19 genes provides a new and reliable strategy for molecular diagnosis of Usher syndrome (USH) and nonsyndromic deafness, particularly appropriate for these disorders characterized by a high clinical and genetic heterogeneity and a complex structure of several of the genes involved. A series of 71 patients including Usher patients previously screened by Sanger sequencing plus newly referred patients was studied. Ninety-eight percent of the variants previously identified by Sanger sequencing were found by next-generation sequencing (NGS). NGS proved to be efficient as it offers analysis of all relevant genes which is laborious to reach with Sanger sequencing. Among the 13 newly referred Usher patients, both mutations in the same gene were identified in 77% of cases (10 patients) and one candidate pathogenic variant in two additional patients. This work can be considered as pilot for implementing NGS for genetically heterogeneous diseases in clinical service. Wiley Periodicals 2014-01 2013-07-10 /pmc/articles/PMC3907913/ /pubmed/24498627 http://dx.doi.org/10.1002/mgg3.25 Text en © 2013 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Besnard, Thomas
García-García, Gema
Baux, David
Vaché, Christel
Faugère, Valérie
Larrieu, Lise
Léonard, Susana
Millan, Jose M
Malcolm, Sue
Claustres, Mireille
Roux, Anne-Françoise
Experience of targeted Usher exome sequencing as a clinical test
title Experience of targeted Usher exome sequencing as a clinical test
title_full Experience of targeted Usher exome sequencing as a clinical test
title_fullStr Experience of targeted Usher exome sequencing as a clinical test
title_full_unstemmed Experience of targeted Usher exome sequencing as a clinical test
title_short Experience of targeted Usher exome sequencing as a clinical test
title_sort experience of targeted usher exome sequencing as a clinical test
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907913/
https://www.ncbi.nlm.nih.gov/pubmed/24498627
http://dx.doi.org/10.1002/mgg3.25
work_keys_str_mv AT besnardthomas experienceoftargetedusherexomesequencingasaclinicaltest
AT garciagarciagema experienceoftargetedusherexomesequencingasaclinicaltest
AT bauxdavid experienceoftargetedusherexomesequencingasaclinicaltest
AT vachechristel experienceoftargetedusherexomesequencingasaclinicaltest
AT faugerevalerie experienceoftargetedusherexomesequencingasaclinicaltest
AT larrieulise experienceoftargetedusherexomesequencingasaclinicaltest
AT leonardsusana experienceoftargetedusherexomesequencingasaclinicaltest
AT millanjosem experienceoftargetedusherexomesequencingasaclinicaltest
AT malcolmsue experienceoftargetedusherexomesequencingasaclinicaltest
AT claustresmireille experienceoftargetedusherexomesequencingasaclinicaltest
AT rouxannefrancoise experienceoftargetedusherexomesequencingasaclinicaltest